The Pharmaceutical Post 20 (4/104)

The Pharmaceutical Post 20The Pharmaceutical Post 20 (4/104)The Pharmaceutical Post 20 - (1/104)The Pharmaceutical Post 20 - (2/104)The Pharmaceutical Post 20 - (3/104)The Pharmaceutical Post 20 - (4/104)The Pharmaceutical Post 20 - (5/104)The Pharmaceutical Post 20 - (6/104)The Pharmaceutical Post 20 - (7/104)The Pharmaceutical Post 20 - (8/104)The Pharmaceutical Post 20 - (9/104)The Pharmaceutical Post 20 - (10/104)The Pharmaceutical Post 20 - (11/104)The Pharmaceutical Post 20 - (12/104)The Pharmaceutical Post 20 - (13/104)The Pharmaceutical Post 20 - (14/104)The Pharmaceutical Post 20 - (15/104)The Pharmaceutical Post 20 - (16/104)The Pharmaceutical Post 20 - (17/104)The Pharmaceutical Post 20 - (18/104)The Pharmaceutical Post 20 - (19/104)The Pharmaceutical Post 20 - (20/104)The Pharmaceutical Post 20 - (21/104)The Pharmaceutical Post 20 - (22/104)The Pharmaceutical Post 20 - (23/104)The Pharmaceutical Post 20 - (24/104)The Pharmaceutical Post 20 - (25/104)The Pharmaceutical Post 20 - (26/104)The Pharmaceutical Post 20 - (27/104)The Pharmaceutical Post 20 - (28/104)The Pharmaceutical Post 20 - (29/104)The Pharmaceutical Post 20 - (30/104)The Pharmaceutical Post 20 - (31/104)The Pharmaceutical Post 20 - (32/104)The Pharmaceutical Post 20 - (33/104)The Pharmaceutical Post 20 - (34/104)The Pharmaceutical Post 20 - (35/104)The Pharmaceutical Post 20 - (36/104)The Pharmaceutical Post 20 - (37/104)The Pharmaceutical Post 20 - (38/104)The Pharmaceutical Post 20 - (39/104)The Pharmaceutical Post 20 - (40/104)The Pharmaceutical Post 20 - (41/104)The Pharmaceutical Post 20 - (42/104)The Pharmaceutical Post 20 - (43/104)The Pharmaceutical Post 20 - (44/104)The Pharmaceutical Post 20 - (45/104)The Pharmaceutical Post 20 - (46/104)The Pharmaceutical Post 20 - (47/104)The Pharmaceutical Post 20 - (48/104)The Pharmaceutical Post 20 - (49/104)The Pharmaceutical Post 20 - (50/104)The Pharmaceutical Post 20 - (51/104)The Pharmaceutical Post 20 - (52/104)The Pharmaceutical Post 20 - (53/104)The Pharmaceutical Post 20 - (54/104)The Pharmaceutical Post 20 - (55/104)The Pharmaceutical Post 20 - (56/104)The Pharmaceutical Post 20 - (57/104)The Pharmaceutical Post 20 - (58/104)The Pharmaceutical Post 20 - (59/104)The Pharmaceutical Post 20 - (60/104)The Pharmaceutical Post 20 - (61/104)The Pharmaceutical Post 20 - (62/104)The Pharmaceutical Post 20 - (63/104)The Pharmaceutical Post 20 - (64/104)The Pharmaceutical Post 20 - (65/104)The Pharmaceutical Post 20 - (66/104)The Pharmaceutical Post 20 - (67/104)The Pharmaceutical Post 20 - (68/104)The Pharmaceutical Post 20 - (69/104)The Pharmaceutical Post 20 - (70/104)The Pharmaceutical Post 20 - (71/104)The Pharmaceutical Post 20 - (72/104)The Pharmaceutical Post 20 - (73/104)The Pharmaceutical Post 20 - (74/104)The Pharmaceutical Post 20 - (75/104)The Pharmaceutical Post 20 - (76/104)The Pharmaceutical Post 20 - (77/104)The Pharmaceutical Post 20 - (78/104)The Pharmaceutical Post 20 - (79/104)The Pharmaceutical Post 20 - (80/104)The Pharmaceutical Post 20 - (81/104)The Pharmaceutical Post 20 - (82/104)The Pharmaceutical Post 20 - (83/104)The Pharmaceutical Post 20 - (84/104)The Pharmaceutical Post 20 - (85/104)The Pharmaceutical Post 20 - (86/104)The Pharmaceutical Post 20 - (87/104)The Pharmaceutical Post 20 - (88/104)The Pharmaceutical Post 20 - (89/104)The Pharmaceutical Post 20 - (90/104)The Pharmaceutical Post 20 - (91/104)The Pharmaceutical Post 20 - (92/104)The Pharmaceutical Post 20 - (93/104)The Pharmaceutical Post 20 - (94/104)The Pharmaceutical Post 20 - (95/104)The Pharmaceutical Post 20 - (96/104)The Pharmaceutical Post 20 - (97/104)The Pharmaceutical Post 20 - (98/104)The Pharmaceutical Post 20 - (99/104)The Pharmaceutical Post 20 - (100/104)The Pharmaceutical Post 20 - (101/104)The Pharmaceutical Post 20 - (102/104)The Pharmaceutical Post 20 - (103/104)The Pharmaceutical Post 20 - (104/104) Sommaire / Contents DOSSIER DURABILITÉ La France en pointe dans la réduction de l’empreinte carbone des inhalateurs aérosols-doseurs France leads the way in reducing the carbon footprint of metered-dose inhalers P.08 INTERVIEW GSK Ventolin low-carbon project: €350 million invested by GSK by the end of 2025 Ventolin low-carbon project: €350 million invested by GSK by the end of 2025 P.14 EXPERT CORNER GERRESHEIMER Conception durable d’un dispositif d’administration de médicaments pour des produits biopharmaceutiques Sustainable design of a drug delivery device 08 for biopharmaceuticals P.18 EXPERT CORNER OLON Projet Ventoline bas carbone : 350 millions d’euros investis par GSK d’ici fin 2025 Olon's Path to Sustainability: Durabilité Transforming Challenges into Opportunities P.30 DOSSIER INJECTABLES Sustainability Vers une diversification des systèmes d’administration par voie parentérale Towards a diversification of delivery systems La France en pointe dans la for parenteral administration P.36 réduction de l’empreinte carbone INTERVIEW NEMERA des inhalateurs aérosols-doseurs Nemera lance un auto-injecteur réutilisable France leads the way lors du CPHI Milan in reducing the carbon Nemera launches a reusable auto-injector footprint of metered-dose in- at CPHI Milan P.42 halers INTERVIEW SYNTEGON Syntegon : « Des équipements adaptés à l'annexe 1 et un Deux laboratoires d’origine étrangère – portefeuille complet de services de mise à niveau via les Chiesi et GSK – investissent de manière systèmes RABS » conséquente en France pour réduire Syntegon: "Equipment adapted to Annex 1 and a complete l’empreinte carbone de leurs inhalateurs de portfolio of upgrade services via RABS systems" P.50 type aérosols-doseurs. EXPERT CORNER STEVANATO GROUP Two foreign pharmaceutical companies - Les avantages des flacons en nest Chiesi and GSK - are investing heavily in pour les produits biologiques lyophilisés France to reduce the carbon footprint of The advantages of nested vials their metered-dose inhalers. for freeze-dried biologics P.66 DOSSIER BIOMANUFACTURING Les stratégies des CDMO pour bousculer le paradigme de mise à l'échelle en bioproduction CDMO strategies for disrupting the biomanufacturing scale-up paradigm P.80 INTERVIEW NOVASIGN « Notre logiciel hybride simule la mise à l'échelle et permet d'économiser jusqu'à 70 % des coûts de développement » Hybrid software simulates scale-up and saves up to 70% in development P.92 INTERVIEW GENEVA BIOTECH Livraison d'ADN de nouvelle génération Next-generation DNA delivery P.98 4 The Pharmaceutical Post 20 / Octobre - 2024